Tag: Hatch-Waxman Act

How Brand Manufacturers Produce Their Own Generic Versions: The Authorized Generics Strategy

How Brand Manufacturers Produce Their Own Generic Versions: The Authorized Generics Strategy

Discover how brand manufacturers produce authorized generics to retain market share after patent expiry. Learn about the production process, pricing strategies, and consumer impact of this pharmaceutical tactic.

Learn More
Federal Circuit Court: Authority on Pharmaceutical Patent Cases

Federal Circuit Court: Authority on Pharmaceutical Patent Cases

The Federal Circuit Court holds exclusive authority over all U.S. pharmaceutical patent cases, shaping how generics enter the market, how patents are challenged, and how dosing innovations are protected. Its rulings on ANDA jurisdiction, Orange Book listings, and obviousness standards have transformed drug development and litigation.

Learn More
Antitrust Laws and Competition Issues in Generic Pharmaceutical Markets

Antitrust Laws and Competition Issues in Generic Pharmaceutical Markets

Antitrust laws in generic drug markets prevent big pharma from blocking cheaper alternatives through pay-for-delay deals, product hopping, and sham petitions. These practices cost consumers billions - and threaten access to life-saving medications.

Learn More
First Generic vs Authorized Generic: How Timing of Market Entry Changes Everything

First Generic vs Authorized Generic: How Timing of Market Entry Changes Everything

First generics and authorized generics both lower drug prices, but when brand companies launch their own generics during the first generic's exclusivity window, they limit price drops and undermine competition. Here's how timing changes everything.

Learn More

© 2026. All rights reserved.